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Background: Since 1989, CF-patients intermittently colonized with Pseudomonas aeruginosa have been treated with inhaled colistin and oral
ciprofloxacin in the Copenhagen CF-centre. The study evaluates 15 years results of this treatment.
Methods: All isolates of P. aeruginosa from CF-patients intermittently colonized with P. aeruginosa from 1989 to 2003 were identified All anti-
P. aeruginosa treatments were evaluated for antibiotics used, treatment duration, pseudomonas-free interval and development of chronic infection.
All P. aeruginosa isolates were assessed for resistance and for non-mucoid or mucoid phenotype.
Results: 146 CF-patients were included in the study (1106 patient-years). 99 patients had first ever isolate during the study period. Median
observation time 7 years (0.1–14.9). 12 patients developed chronic infection. A Kaplan Meyer plot showed protection from chronic infection in up
to 80% of patients for up to 15 years. 613 colistin/ciprofloxacin treatments were given. There was no difference in pseudomonas-free interval
comparing 3 weeks (5 months) and 3 months (10.4 months) of colistin and ciprofloxacin, but a significant difference compared to no treatment
(1.9 months). Patients developing chronic infection had significantly shorter pseudomonas-free interval after treatment of first ever isolate
compared to patients remaining intermittently colonized (pb0.003). Treatment failure (P. aeruginosa-positive culture immediately after ended
treatment of first ever isolate) was a strong risk factor for development of chronic infection after 3–4 years, OR 5.8. 1093 pseudomonas-isolates
were evaluated (86.6% non-mucoid). No colistin-resistance was found. Ciprofloxacin-resistance was found in 4% of isolates.
Conclusion: Treatment of intermittent P. aeruginosa colonization in CF-patients using colistin and ciprofloxacin can protect up to 80% of patients
from development of chronic infection for up to 15 years. A positive culture immediately after treatment of first ever isolate is a strong risk factor
for development of chronic infection. We found no colistin-resistance and minimal ciprofloxacin-resistance.
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Cystic fibrosis (CF) is characterised by recurrent coloniza-
tion and ultimately chronic infection of the lower airways.
Pseudomonas aeruginosa is the most common pathogen; up to
80% of the adult CF population is chronically infected with
P. aeruginosa. Chronic airway infection is a major cause of the
increased morbidity and mortality observed in patients with CF
[1–3].
Chronic airway infectionwithP. aeruginosa is usually preceded




All (N=146) First ever isolate in
study (N=99)
Age at diagnosis 0.5 years (0–13) 0.5 years (0–13)
Observation time 7.6 years (0.1–15) 7 years (0.1–14.9)
Age at 1st ever isolate 4.2 years (0–28.1) 4.8 years (0.3–28.1)
Number of isolates in the study 5.5 (1–41) 5 (1–29)
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P. aeruginosa in airway secretions, development of anti-
P. aeruginosa antibodies and also by a change in phenotype of
the microorganism from non-mucoid to mucoid. Once chronic
infection is established, durable eradication is impossible.
During the 1970s and 1980s, treatment of chronic pseudo-
monas infection became possible, thanks to an increasing
number of i.v. antibiotics and to the possibility of treatment with
inhaled and oral drugs [5]. In 1989, treatment of intermittently
colonized patients using inhaled colistin and oral ciprofloxacin
was tried with encouraging results [6] and after a few years,
treatment of these patients became standard in the Copenhagen
CF centre. At first patients were treated for 3 weeks, but after a
few years the “Copenhagen Model” was established (Table 1)
[7,8]. This treatment strategy is a combination of inhaled colistin
and oral ciprofloxacin used with increasing dosage and for
increased duration at re-infections. Being one of the first anti-
P. aeruginosa antibiotics available for inhalation in addition to
inhaled aminoglycosides, inhaled colistin has been used for
about 20 years in Europe [5,9–12]. Oral ciprofloxacin has also
been extensively used for pseudomonas infections in CF patients
since the mid-1980s [9,13,14].
In 1996 an intern-analysis of colistin and ciprofloxacin
treatments efficacy for 3 weeks and 3 months was performed.
Results showed a significantly longer pseudomonas free period in
the group of patients receiving 3 months' treatment [8], and
standard treatment was changed to step 3 for all isolates of
P. aeruginosa in intermittently colonized patients: 3 months of
inhaled colistin, 2MIE t.i.d. and oral ciprofloxacin, 25–50mg/kg/
day divided in two doses (Table 1) [7,8]. During the late 1990′s
treatment with DNA-se (Pulmozyme®) was initiated; first in
patients chronically infected with P. aeruginosa and then as
standard treatment in the entire CF population after 1996.
The aim of the present study was to evaluate 15 years
experience with treatment of intermittent P. aeruginosa-coloniza-
tion in CF patients using inhaled colistin and oral ciprofloxacin in
the Copenhagen CF centre. We assessed the efficacy of the
treatment by means of time to recurrence of P. aeruginosa in
airway secretion and evaluated development of chronic infection,
number and type of treatments and possible development of
resistance.
2. Materials and methods
The study is a descriptive, retrospective cohort study. A cohort
of 296 CF patients is followed at the Copenhagen CF centre: allTable 1








1st isolate 1 mio. units a b.i.d. 10–20 mg/kg b.i.d. 3 weeks
2nd isolate 2 mio. units t.i.d. 10–20 mg/kg b.i.d. 3 weeks
3rd and subsequent
isolates
2 mio. units t.i.d. 10–20 mg/kg b.i.d. 3 months
a 1 mg colistin base=30,000 international units.patients are seen every month in the out patient clinic, and at each
visit a sputum sample or lower respiratory tract secretions,
obtained by endo-laryngeal suctioning, is examined for the
presence of microorganisms as described previously [1]. All
patients free of chronic infection and intermittently colonizedwith
P. aeruginosa between 1 January 1989 and 31 December 2003
were identified and included in the study at the time of first isolate
of P. aeruginosa during the study period. Patients were followed
until study end in 2003, or excluded at the time of establishment of
chronic infection or time of death or loss to follow-up. All anti-
P. aeruginosa treatments were counted and evaluated for
antibiotics used and treatment duration.
Patients with first ever isolate ofP. aeruginosa during the study
period were identified. These patients had not had any un-treated
isolates prior to 1989 and this group was evaluated for effect of the
treatment policy of the centre. Effect was measured as time to next
isolate ofP. aeruginosa, and for development of chronic infection.
Treatment failure was defined as a P. aeruginosa-positive culture
during treatment or immediately after ended treatment.
For patients developing chronic infection, time-period from
first ever isolate of P. aeruginosa to establishment of chronic
infectionwas assessed. Copenhagen definition of chronic infection
is defined as 6 consecutive monthly sputum samples with growth
of P. aeruginosa or — in case of shorter colonization — rise in
specific, precipitating antibodies against P. aeruginosa to at least 2
[1,15]. Intermittently colonized patients are defined as patients
with at least one isolate of P. aeruginosa, but normal levels of
precipitating antibodies against P. aeruginosa.
Patients were also assessed for development of chronic
infection according to Leeds criteria [16]; when more than 50%
of months, when samples had been taken, were P. aeruginosa
culture positive.
All sputum samples obtained in the study period were
evaluated for inclusion. Bacteriological investigation comprises
isolation and identification of P. aeruginosa, assessment for
mucoidity, primary sensitivity testing (using agar-diffusion) to
anti-P. aeruginosa antibiotics including ciprofloxacin (suscep-
tible strains MIC b0.2 μg/ml, resistant strainsN1 μg/ml) and
colistin (susceptible strains MIC b4 μg/ml, resistant strains
≥4 μg/ml) [17] (Neosensitabs®, Rosco, Copenhagen, Den-
mark). All P. aeruginosa positive cultures during the study
period were included.
2.1. Statistic
Pseudomonas-free interval after treatment and time to
development of chronic infection were expressed as a Kaplan–
Table 3
Treatment of isolates: number (percentage of all isolates)
Interval Colistin and ciprofloxacin Other treatments a No treatment
1989–1991 139 (62.6%) 16 (7.2%) 67 (30.2%)
1992–1994 115 (73.7%) 12 (7.7%) 29 (18.6%)
1995–1997 141 (79.7%) 31 (17.5%) 5 (2.8%)
1998–2000 124 (73.8%) 37 (22%) 7 (4.2%)
2001–2003 93 (56.4%) 68 (41.2%) 4 (2.4%)
a Other treatments: inhaled antibiotics (colistin, tobramycin, ceftazidim) and/
or oral antibiotics (ciprofloxacin, azithromycin). In many cases, patients were
treated with i.v. antibiotics (beta-lactam in combination with tobramycin),
followed by treatment as described above.
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aeruginosa free interval. Ciprofloxacin-resistance over time was
compared using Pearson correlation. Success or failure in
different treatments was compared using Chi-square test. Odds




146 patients (72 males) were intermittently colonized with P.
aeruginosa during the study period, of these, 99 patients (46
males) had first ever isolate of P. aeruginosa after 1989 (Table 2).
1 patient was lost to follow-up and 1 patient died during the study
period. The study includes 1106 patient years.
3.2. Treatments
The 146 patients included in the study received 777 treatments;
613 treatments were a combination of inhaled colistin and oral
ciprofloxacin, 164 treatments were combinations of otherFig. 1. Change in treatment-duration of colistin and ciprofloxacin; nuantibiotics. 130 colonization episodes were not treated, mainly
in the beginning of the period, when treatment had yet to become
standard of the centre (Table 3). The remaining 186 isolates were
either found during treatment or in patients treated for chronic
infections caused by other Gram-negative microorganisms. Only
treatments with colistin and ciprofloxacin were further evaluated
in the study.
Duration of treatment with colistin and ciprofloxacin was
evaluated (Fig. 1). During the study, an increasing number of
treatments lasted 3 months, as standard treatment of all isolates
was changed to 3 months (step 3 in the “Copenhagen model”,
Table 1). 69 treatments lasted more than 3 months.
3.3. Treatment effect
In the group of 99 patients with first ever isolate during the
study period, we identified 359 colonization episodes, 33 (9.2%)
colonization episodes were not treated, 87 (24.2%) colonization
episodes were treated for 3 weeks and 239 (66.6%) colonization
episodes were treated for 3 months (Fig. 2). In the non-treatment
group, median time to recurrence of P. aeruginosa was
1.9 months (range 0–58.3 months). In the group treated for
3 weeks, median time to recurrence of P. aeruginosa was
5 months (range 0.2–112.8 months), and in the group treated
for 3 months, median time to recurrence of P. aeruginosa was
10.4 months (range 0–98.2). The difference between no
treatment and any treatment was significant at all times
(pb0.02). The difference between 3 weeks and 3 months of
treatment was not significant.
When looking at time to recurrence of P. aeruginosa after
treatment of first ever isolate with 3 weeks or 3 months of colistin
and ciprofloxacin in the 99 patients with first ever isolate during
the study, the group of patients eventually developing chronic
infection had a significantly (pb0.003) shorterP. aeruginosa-free
interval between first ever and second isolate when comparing tomber of treatments of different lengths during the study period.
Fig. 2. Proportion of patients still free of pseudomonas after treatment with colistin and ciprofloxacin.
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study period (Fig. 3).
Treatment failure after treatment with colistin and cipro-
floxacin for first ever isolate was a risk factor for later
development of chronic infection, OR 5.8 (95% confidence
interval 1.34–25.14).
3.4. Development of chronic infection
Of the 99 patients with first ever isolate in the study, 12
patients developed chronic infection according to the Copenha-
gen definition after a median of 3.7 years after first ever isolate
(0.5–10.3 years), and a Kaplan Meyer estimate showed that up
to 80% of patients were protected against development of
chronic infection for up to 15 years (Fig. 4).
All 99 patients were assessed for chronic infection using
Leeds criteria [16] at any time based on previous 12 months,
more than 50% of months, when samples had been taken, wereFig. 3. P. aeruginosa-free interval after treatment of first ever isolate in patients who
chronic infection.P. aeruginosa culture positive. Of the 12 patients developing
chronic infection according to the Copenhagen criteria, all
patients became chronically infected according to the Leeds
criteria. 2 patients had a chronic infection by the Leeds criteria
5 months and 2 years, respectively, prior to the onset of chronic
infection by the Copenhagen criteria. 3 patients became
chronically infected according to both criteria at the same
time, and in 7 patients, chronic infection according to the Leeds
criteria developed a median of 1 year (range 0.3–12.7 years)
after development of chronic infection by the Copenhagen
criteria. Of the 87 patients not developing chronic infection by
the Copenhagen criteria, 3 patients at one time fulfilled the
Leeds criteria of chronic infection, but went back to intermittent
colonization according to the Leeds criteria.
All patients included in the study had specific, precipitating
anti-P. aeruginosa antibodies b2 at inclusion, and 10 of the 12
patients developing chronic infection had increasing precipitating
antibodies to at least 2 at time of establishment of chronic infection.eventually did develop chronic infection and patients without development of
Fig. 4. Proportion of patients without chronic infection in patients with first ever isolate in the study period.
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From the 146 patients included in the study, 1093 isolates of
P. aeruginosa (946 non-mucoid, 147 mucoid isolates) were
assessed for resistance to colistin and ciprofloxacin. We found
no isolates resistant to colistin in intermittently colonized
patients in the study period.
44 ciprofloxacin-resistant isolates were found in 30 inter-
mittently colonized patients. 8 patients harboured ciprofloxacin-
resistant strains more than once. First ciprofloxacin-resistant
isolate was found a median of 1.6 years after first dose of
ciprofloxacin (range 0–13.9 years), and after a median of
24 weeks of total ciprofloxacin-treatment (range 0–99 weeks).
In all patients, the occurrence of ciprofloxacin-resistant isolates
was intermittent, since the resistant strain subsequently
disappeared.
4% of all isolates included in the study were ciprofloxacin-
resistant; 39 of 946 non-mucoid isolates (4.1%) and 5 of 147
mucoid isolates (3.4%) were ciprofloxacin-resistant (n.s.).
There was no increase in the occurrence of ciprofloxacin-
resistant isolates over time.
4. Discussion
Treatment policy of CF patients colonized with P. aerugi-
nosa in the airways using inhaled colistin and oral ciprofloxacin
has evolved over the last 15 years in the Copenhagen CF centre
[6–8,18]. A 3 weeks treatment developed into the “Copenhagen
model” (Table 1) and has now become a standard treatment of
3 months of colistin and ciprofloxacin for all intermittent
colonisation episodes. The implementation of this treatment has
resulted in an increasing proportion of the patient population
free from chronic P. aeruginosa infection of the airways [19,20]
even into adulthood, resulting in improvement of lung function
compared to historic controls [7]. Preservation of normal lung
function in CF patients free of chronic P. aeruginosa infection
[21] could ultimately lead to increased survival in these patients,since respiratory failure following chronic P. aeruginosa
infection is still a very common cause of increased mortality
in CF, although introduction of antibiotic treatment has
modified the outcome of chronic P. aeruginosa infection [19].
Most CF centres agree on treating young CF patients
intermittently colonized with P. aeruginosa [8,9,22–34]. Most
centres use inhaled antibiotics alone or in combination with oral
ciprofloxacin either as primary treatment or after a course of i.v.
antibiotics. Treatment duration varies among centres. The
combination of antibiotics for this treatment is not yet defined
[35].
As can be seen from the present study, an official treatment
strategy of a CF centre does not automatically lead to the use of
this strategy in all patients. Individual treatments depend on
many things; implementation of a treatment strategy in the
centre, compliance, exacerbations, early signs of evolving
chronic infection and adverse effects of the treatment. Similar
results have been reported by others [23,32].
The median time to recurrence of P. aeruginosa was
5 months for 3 weeks treatment and 10.4 months for 3 months
treatment, this difference was not significant. The difference
between 5 and 10.4 months could still be clinically relevant,
however, leading to the difference between one or two
treatments for P. aeruginosa in a year in individual patients,
but also to the difference between 3 months or 6 weeks of total
treatment time in a year in individual patients. We found 1093
isolates of P. aeruginosa in 1106 patient years in this study, and
on average, every patient should have received one treatment a
year, if all isolates had been treated according to the treatment
protocol of our centre.
The present study shows a median time to recurrence of P.
aeruginosa similar to results reported by other groups on
treatment of intermittently colonized CF patients: Taccetti et al.
[27] found a median time to recurrence of P. aeruginosa of
18 months (range 4–80). Munck et al. [25] found a median time
to recurrence of P. aeruginosa of 8 months (range 3–25).
Treatment was very intensive: 2–3 weeks of i.v. antibiotics
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Both studies used genotyping of P. aeruginosa to assess
whether next colonization was re-infection with identical strains
or colonization with a new strain of P. aeruginosa. This aspect
was not included in the present study.
Although not directly comparable, since different definitions
of intermittent colonization and chronic infection have been
used in different groups, several other studies have also reported
a positive effect of treatment of intermittent P. aeruginosa
colonization in CF patients without reporting time to recurrence
of infection. Lee et al. [32] found a reduction in prevalence of
chronic P. aeruginosa infection in CF patients following
introduction of early treatment.
Treatments with inhaled tobramycin showed similar results:
Gibson et al. [29], Ratjen et al. [26], Wiesemann et al. [36],
Griese et al. [33], all report successful eradication without
studying the time to recurrence of infection. In the studies by
Ratjen et al. and by Griese et al., the inclusion criteria was not
one but at least two cultures positive for P. aeruginosa; a
positive culture after screening and then confirmation by a
second positive culture within a month, to exclude patients with
transient colonization. Heinzl et al. [23] studied prophylactic
gentamicin in CF patients with risk factors for establishment of
chronic pseudomonas-infection, but did not look at intermittent
colonizations. Nixon et al. [3] reported on treatment of 24
patients with pseudomonas infection diagnosed by BAL. After
treatment, 25% were pseudomonas-negative for more than
1 year. This number is lower than the results of other studies, but
could be due to the facts that BAL was only done once yearly,
and some patients may therefore have been colonized with P.
aeruginosa for up to one year before receiving treatment,
secondly, some patients were colonized by a multi-resistant
mucoid strain, making eradication very hard indeed, if at all
possible.
Quite surprisingly, patients who would develop chronic
infection in 3–4 years had significantly shorter P. aeruginosa-
free interval between first ever and second isolate compared to
patients not developing chronic infection, and treatment failure
defined as a P. aeruginosa positive culture during treatment or
immediately after ended treatment for first ever isolate was a
strong risk factor for development of chronic infection 3–
4 years after first ever isolate. This finding might be a very
useful clinical tool identifying patients at increased risk of
developing chronic infection. Earlier results from our centre by
Pressler et al. has shown that already 3 years prior to
establishment of chronic infection, elevated anti-P. aeruginosa
antibodies can be found in these patients compared to patients
not developing chronic infection [37]. Measurement of anti-P.
aeruginosa antibodies already at the time of the first P.
aeruginosa isolates in the history of a CF-patient could further
help identifying patients at increased risk of developing chronic
infection. These patients might be examined for possible focus
of infection and possibly needs even more aggressive antibiotic
treatment for longer periods of time compared to the standard
treatment, as reported by Høiby et al. [8].
In the present study, 12 of the 99 patients with first ever
isolate after 1989 developed chronic infection during the studyperiod. There was good agreement between the Copenhagen
and the Leeds criteria; although the time of development of
chronic infection varied a few years depending on the criteria
used, all patients developing chronic infection by one definition
also became chronically infected according to the other
definition. An earlier study by Proesmans et al. [38] has also
shown very good agreement between levels of specific anti-P.
aeruginosa antibodies and the Leeds criteria in identifying CF
patients chronically infected with P. aeruginosa in a Belgian CF
population.
In the present study all patients who fulfil Copenhagen criteria
of chronic infection are treated continually with inhaled
antibiotics, possibly explaining why most patients were defined
as having chronic infection on basis of increased anti-
P. aeruginosa antibodies, not on the basis of 6 consecutive
positive cultures. This could also explain the delay in chronic
infection by the Leeds criteria compared to the Copenhagen
criteria in 7 of the 12 patients developing chronic infection during
the study.
Up to 80% of patients in the Copenhagen CF centre were
protected from development of chronic infection for up to
15 years after first isolate of P. aeruginosa using the present
treatment-strategy (Fig. 4). Thus, the previously published
results have now been confirmed based on a much longer
observation period [7].
Compared to other antibiotics used for pseudomonas infection
in cystic fibrosis, colistin rarely induces or selects for resistance in
intermittently colonized patients. Pitt et al. [39] found 96.9% of
417 CF isolates of P. aeruginosa to be colistin-susceptible (MIC
≤4 μg/ml), while Schülin [40] found only 34.9% of non-mucoid
strains and 51.9% ofmucoid strains ofCF isolates ofP. aeruginosa
to be colistin-susceptible. However, the MIC-breakpoint used in
that study was MIC ≤0.5 μg/ml. If using MIC ≤4 μg/ml as
breakpoint of susceptibility, 87.8% of non-mucoid isolates and
98.1% of mucoid isolates were susceptible to colistin [41]. In our
study, with breakpoint of susceptibility MIC ≤4 μg/ml (Neo-
sensitabs®) [17], we did not find any isolates resistant to colistin in
intermittently colonized patients.
In CF patients chronically infected with P. aeruginosa,
colistin-resistant isolates have been found in patients treated
with inhaled or intravenously administered colistin [42,43].
These isolates have been found able to spread among CF
patients attending the same CF centre. In the Copenhagen CF
centre, similar occurrence of colistin-resistant isolates in
chronically infected patients has been found [44,45]. The
patients shared colistin-resistant isolates originating from the
same clone indicating cross-infection. This ability to cause
cross-infection might be responsible for a higher frequency of
colistin-resistant isolates found in sub-groups of chronically
infected patients than in groups of patients where cross-
infection is prevented. It has been shown, however [43], that use
of colistin in the treatment of CF patients predisposes for
development of colistin-resistance by demonstrating increased
MIC-levels in pseudomonas isolates found in colistin treated CF
patients compared to colistin naïve patients.
We found a low level of resistance to ciprofloxacin in the
present study; few percent included in the study were resistant,
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ciprofloxacin-resistant (MIC≥8 μg/ml) and Schülin [40] found
15.8% of isolates to be ciprofloxacin-resistant (MIC≥8 μg/ml).
These studies include non-mucoid and mucoid isolates from CF
patients. Whether patients where chronically or intermittently
colonized was not reported. Chronically colonized patients
receive more antibiotic treatments, and the occurrence of
resistance is more frequent in chronically colonized patients
[46], probably due to a higher bacterial load and increased
mutation frequency. In intermittently colonized patients, the
number of microorganisms is smaller and mutation frequency
lower, explaining the low occurrence of resistance [47].
Ciprofloxacin was used in combination with colistin at all
times, further explaining the low occurrence of resistance. Our
study includes only intermittently colonized patients, but still 30
of 146 patients (20.4%) of patients had been harbouring a
ciprofloxacin-resistant strain at some time. Most patients had
received ciprofloxacin for some time (median treatment-
duration 24 weeks), but 2 patients had not received ciproflox-
acin prior to the occurrence of a ciprofloxacin-resistant isolate.
In all patients, the occurrence of ciprofloxacin-resistance was
intermittent, and even though the treatment length with colistin
and ciprofloxacin increased during the study period (Fig. 1), the
percentage of isolates with ciprofloxacin-resistance did not
increase over time.
5. Conclusion
Use of inhaled colistin and oral ciprofloxacin as treatment of
CF patients intermittently colonizedwithP. aeruginosa postpones
the next occurrence of P. aeruginosa compared to no treatment,
and protects up to 80% of patients from development of chronic
infection for up to 15 years. A P. aeruginosa-positive culture
during treatment or immediately after treatment for first ever
isolate ofP. aeruginosa is a risk factor for development of chronic
infection, and these patients should be followed closely.
Treatment with colistin and ciprofloxacin leads to minimal
ciprofloxacin-resistance and does not lead to colistin-resistance
in intermittently colonized patients.
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